1Other quality system
Complete testing was not performed according to the requirements.
Inspection Record
Aurium Pharma Inc. — Health Canada Inspection Findings
View the regulator's official source The source document is always the basis for judgement.
Findings
2Other quality system
The assessment, documentation, and/or procedures for considering the resale of returned drugs were inadequate.
3Complaint and recall handling
Investigations into deviations, reports, and/or follow-up actions were inadequate. The assessment, recording, follow-up, and/or investigation of complaints and/or other information about potentially defective products was inadequate.
4Stability and storage
The ongoing stability program for a drug was inadequate.
5Other quality system
The handling of standard operating procedures for good manufacturing practices was inadequate. The recorded information or details were inadequate.
About this record
Extracted automatically from the document of the Health Canada inspection on 2026-01-13. The source is available at the link above.
This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.
Translation and classification are automated and may differ in nuance from the source.
